Dual Receptor Agonist
Tirzepatide
GLP-1 / GIP Dual Receptor Agonist
Tirzepatide is a synthetic 39-amino acid peptide and the first approved dual GLP-1/GIP receptor agonist (approved as Mounjaro). It demonstrates dual agonism at glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), making it a highly relevant research compound for metabolic and glycaemic regulation research.
Quantity
10MG
Purity
98%+
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION
Research Information
- Dual agonist at GLP-1R and GIPR — the first approved compound of this class
- Superior glycaemic control versus GLP-1 monotherapy in clinical comparisons
- Studied for adipose tissue metabolism and lipid handling research applications
- Weekly dosing paradigm validated in Phase III SURPASS trial program
- Key research tool for comparing dual versus triple incretin receptor activation
Storage Conditions
- Long-term: −80°C lyophilised
- Reconstituted: 4°C, use within 4 weeks
- Avoid freeze-thaw cycles
Safe Handling
- For laboratory research use only
- Handle with appropriate PPE
Frequently Asked
COMPOUND FAQ
Continue Exploring
RELATED COMPOUNDS
Triple Receptor Agonist
Retatrutide
A next-generation triple incretin receptor agonist demonstrating potent multi-receptor activity in preclinical research models.
Reconstitution Solution
BAC Water
Sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative. The standard reconstitution vehicle for research peptide compounds.
COMING SOON
GLP-1 Agonist
Semaglutide
A long-acting GLP-1 receptor agonist and one of the most extensively studied incretin mimetics, with applications across metabolic, cardiovascular, and neuroendocrine research.
RESEARCH USE ONLY: Tirzepatide is sold exclusively for in vitro laboratory research. Not intended for human or animal consumption. Not for clinical or therapeutic use.